PROTACs - Targeted Protein Degradation: Promises and Challenges Ahead

September 29, 2020 12:00 PM - 1:00 PM

Webinar, click "live-stream" button to view

Add to Calendar 9/29/2020 12:00:00 PM 9/29/2020 1:00:00 PM PROTACs - Targeted Protein Degradation: Promises and Challenges Ahead Targeted protein degradation is an emerging therapeutic modality which has made tremendous progress and attracted massive investment in recent years. This modality is a class of bifunctional small molecules composed of an E3 ligase binder linked to a target protein binding moiety. It offers the possibility to degrade any intracellular target proteins regardless if there is a well-defined binding pocket in the target protein. Therefore, it opens numerous opportunities to drug many previously unreachable targets. However, the molecules tend to be bulky, floppy, greasy, and lack drug likeness properties. Nevertheless, increasing preclinical animal data has demonstrated the desired efficacy. Very recently, the early clinical safety and PK results are encouraging. In this forum our expert panel will share key learnings about this novel modality and discuss strategies to overcome potential challenges ahead.

Sponsored by MassBio's Drug Discovery forum working group.


MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning. Webinar, click "live-stream" button to view
Senior Vice President, Biology at C4 Therapeutics
Roy is Senior Vice President of Biology at C4 Therapeutics. Prior to joining C4 Therapeutics, Dr. Pollock was Vice President of Biology at Warp Drive Bio (acquired by Revolution Medicines) where he guided the discovery and characterization of inhibitors targeting the activated form of mutant KRAS using a novel tri-complex technology platform. Prior to joining Warp Drive, Dr. Pollock was at Epizyme where he led biology support for histone methyltransferase inhibitors targeting DOT1L (Pinometostat) and EZH2 (Tazverik™) from hit identification through to entry into Phase I clinical trials. Prior to Epizyme, Dr Pollock worked in oncology drug discovery at Merck Research Laboratories and ARIAD Pharmaceuticals. He holds a B.Sc. in biochemistry from St Andrews University in Scotland and a Ph.D. in Molecular Biology from Imperial College London.